HHS Taps BioCryst for Ebola Drug Experiments; Robin Robinson Comments
BioCryst Pharmaceuticals will experiment on a new drug to treat the Ebola virus under a potential $35 million contract with the Department of Health and Human Services. Studies on the experimental drug will occur over the next 18 months in collaboration with the Biomedical Advanced Research and Development Authority prior to large-scale production, HHS said Tuesday. […] More